GSK’s Blenrep Shows Promise in Multiple Myeloma Trial

GlaxoSmithKline (GB:GSK) has released an update.

GSK plc announced promising results from its DREAMM-7 phase III trial, highlighting that its drug Blenrep, combined with bortezomib and dexamethasone, significantly improves survival rates for patients with relapsed or refractory multiple myeloma compared to standard treatments. These findings are set to be presented at the upcoming American Society of Hematology Annual Meeting and have bolstered GSK’s efforts to secure regulatory approval across various regions. Investors might find these developments encouraging as they underscore GSK’s potential impact on the oncology market.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.